Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KH110
- Development stage
- Phase 2
- Lead developer
- Chengdu Kanghong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KH110 is an innovative proprietary Chinese patent medicine developed for the treatment of Alzheimer's disease. It is also known as Wujia Yizhi granule and is currently in Phase II clinical trials in China. The drug has shown promising preclinical efficacy, but its precise mechanism of action has not been disclosed publicly. It represents a novel approach to Alzheimer's therapy from Kanghong Pharmaceutical, aiming to address the unmet need for effective treatments for this progressive neurodegenerative disorder[1][2].
- Brand names
- Wujia Yizhi granule
- Other names
- Wujia Yizhi granuleKH110KH-110KH 110
Beyond the preview
Go deeper on KH110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KH110.